Japan’s 2025 AI Bill highlights a regulatory change that values innovation rather than restriction, specifically in the pharmaceutical industry. In contrast with the EU’s rule-based system, Japan promotes voluntary compliance and collaboration, with flexible guidelines that speed up drug development. While this model requires robust internal regulation, it leaves room for quicker innovation.
The nation’s data infrastructure is also getting better. Pseudonymized patient data can now be connected across hospitals under the Next-Generation Medical Infrastructure Law that aids the production of real-world evidence in regulatory filings. Of course, there remain issues, such as fragmented datasets and uneven institutional engagement, but the move from opt-in to opt-out consent represents a great improvement.
Large companies, like Astellas, Chugai, and Fujitsu, are actually embedding AI across their operations. Government-supported programs, such as Generative AI Accelerator Challenge (GENIAC), are encouraging collaboration between academia and industry. These actions are starting to break up silos across different sectors and expand the AI innovation ecosystem in Japan.
Nevertheless, drug lag in Japan is still a problem. AI holds the promise to simplify clinical trials, hasten regulatory evaluations, and bridge gaps in approvals. As the industry continues to change, AI is becoming the infrastructure backbone, from R&D to manufacturing and beyond. With the Japanese AI market projected to expand more than 40% each year through 2030, Japan needs to move boldly to catch up with the West.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.